Her­ceptin founder snags $158M for his UCLA-biotech part­ner­ship TORL Bio­Ther­a­peu­tics

One of the key re­searchers be­hind iden­ti­fy­ing HER2 as a breast can­cer tar­get — and turn­ing that dis­cov­ery in­to what be­came the block­buster Her­ceptin — has formed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER